GLP-1 Drugs: Beyond Obesity

GLP-1 drugs are helping millions of people worldwide control their Type 2 diabetes and lose weight. Beyond obesity, many researchers and drug developers are investigating the next chapter in the evolution of these so-called glucagon-like peptide-1 receptor agonists (GLP-1). If the work pans out, these popular therapies could one day be repurposed to treat Alzheimer’s disease, addiction, Parkinson’s disease, autoimmune diseases, and the liver disease NASH. Watch our video to learn more.

For more information:

Visit criver.com for more information about cardiovascular and metabolic disease studies, including diet-induced models and metabolic dysfunction-associated steatohepatitis (MASH) models.

Check out this recent Eureka blog article from our scientific experts, Blandine Mille Baker, Elisa Pasqua, and Aditya Ambade, about the new terrain being explored by GLP-1 drug developers and their partners.